RE:RE:Potential Rise It might not be for nothing that the FDA is going for standard review time for IBRX rather than priority review? Although they got BTD which normally means priority review. Perhaps they are waiting to see TLD-1433 data to decide if a combination trial drug needs to be even higher efficacy than best single drug? I'dont know, but if a single agent produces the same results as a combo drug, then maybe the combo drug needs a randomized control trial in order to compare true efficacy relative to comparator.?. Just IMO most probably not related, but got me thinking.
N0taP00p wrote: I did own SESN for a while and then sold. May have a few hundred still left. In TLTs case, the anticipation will be AA after BTD, so hoping any spike will sustain itself. Curious to see what happens with IBRX. Their next decision from the FDA is expected around May, I think.
enriquesuave wrote: I remember about 4 years ago when SESN bio went from 0.60 to over $3 ( from February to May a gradual increase) in anticipation of preliminary 90 days data readout on about 55 patients. The anticipation was to see if doubling the number of treatments from 1 per week to 2 instillations per week would increase efficacy seen in PH2 of 40% at 90 days. It didn't and no increase in efficacy was noted, and SP went down gradually to around $1. Can we see the same happen here but go even higher on favourable data?